By Ana Espino | Published on February 2, 2026 | 3 min read
Osteoporosis is a chronic skeletal disorder
characterized by a progressive loss of bone mineral density (BMD) and deterioration
of bone microarchitecture. This increased fragility exposes patients —
particularly postmenopausal women — to a high risk of fractures, often
occurring without prior symptoms. According to the WHO, over 200 million
people worldwide are affected, with a major incidence after the age of
50.
Current management is primarily
based on pharmacological treatments such as bisphosphonates, selective
estrogen receptor modulators (SERMs), or hormone replacement therapy. Although
effective, these treatments have significant limitations : side effects
(gastrointestinal, cardiovascular), poor adherence, and heterogeneous response
across patients. These constraints highlight the need for complementary
strategies that are safer and better tolerated.
Among emerging approaches, probiotics
are gaining increasing attention. Their ability to modulate the gut microbiota
could positively impact bone health via the gut–bone axis, by enhancing
calcium absorption, reducing systemic inflammation, and regulating osteoblastic
and osteoclastic activity.
In this context, the present study
aimed to assess the clinical effects of probiotic supplementation on bone
formation and resorption markers in older adults with osteoporosis or
osteopenia.
Could bacteria reshape our bones?
Fifteen randomized clinical trials
including
1,432 participants over the age of 50 were selected. Intervention
durations ranged from 8 weeks to 12 months. The
probiotics studied included
strains from Lactobacillus, Bifidobacterium, and Saccharomyces, administered
individually or in combination, at doses ranging from
10⁸ to 10¹¹ CFU/day.
These studies enabled an in-depth
analysis of key bone remodeling biomarkers. Markers of bone formation
showed significant improvements, with an increase in P1NP of +8.4 mg/L and a
modest but significant rise in osteocalcin. In terms of bone resorption, a
significant reduction in CTX-I—a direct indicator of type I collagen breakdown—was
observed. However, the effects on NTX and TRAP-5b remained variable and overall
non-significant.
Multi-strain formulations proved more effective than
single-strain ones, both in stimulating bone formation and reducing resorption.
A clear dose–response effect was observed, particularly for P1NP. Furthermore,
postmenopausal women experienced more marked benefits compared to mixed-gender
groups.
Sensitivity analyses confirmed the
robustness of the results, and no significant publication bias was detected for
the main markers (P1NP, CTX-I).
A Microbial Cure to Strengthen the Future?
Osteoporosis is a condition
characterized by increased bone fragility and elevated fracture risk. Despite
the availability of pharmacological treatments, management remains limited by
side effects, low adherence, and inconsistent efficacy.
In light of these challenges, this
study aimed to assess the potential of probiotics as an adjunctive strategy
to modulate bone remodeling. The results confirm a favorable impact of
supplementation, particularly through increased levels of bone formation
markers (P1NP, osteocalcin) and reduced resorption (CTX-I), with enhanced
benefits seen in multi-strain and long-duration interventions.
However, limitations remain and justify further research. These
future studies should include long-term trials with improved control of
methodological bias, standardization of probiotic strains, and broader
representation of under-studied populations. A deeper investigation into strain-specific
mechanisms, particularly through the gut–bone axis, will also be essential
to refine clinical recommendations.
Read next: Epigenetic regulation in osteoporosis
About the author – Ana EspinoPhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
